Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Tracy Todd Batchelor, M.D.

Co-Author

This page shows the publications co-authored by Tracy Batchelor and Rakesh Jain.
Connection Strength

6.714
  1. Increased perfusion due to vascular normalization improves oxygenation and survival in glioblastoma patients treated with cediranib with or without chemoradiation. Neuro Oncol. 2014 Jul; 16 Suppl 3:iii12.
    View in: PubMed
    Score: 0.623
  2. Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci U S A. 2013 Nov 19; 110(47):19059-64.
    View in: PubMed
    Score: 0.596
  3. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol. 2010 Jun 10; 28(17):2817-23.
    View in: PubMed
    Score: 0.468
  4. Angiogenesis in brain tumours. Nat Rev Neurosci. 2007 Aug; 8(8):610-22.
    View in: PubMed
    Score: 0.386
  5. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007 Jan; 11(1):83-95.
    View in: PubMed
    Score: 0.371
  6. Vascular dysfunction promotes regional hypoxia after bevacizumab therapy in recurrent glioblastoma patients. Neurooncol Adv. 2020 Jan-Dec; 2(1):vdaa157.
    View in: PubMed
    Score: 0.243
  7. Bevacizumab Reduces Permeability and Concurrent Temozolomide Delivery in a Subset of Patients with Recurrent Glioblastoma. Clin Cancer Res. 2020 01 01; 26(1):206-212.
    View in: PubMed
    Score: 0.224
  8. Solid stress in brain tumours causes neuronal loss and neurological dysfunction and can be reversed by lithium. Nat Biomed Eng. 2019 03; 3(3):230-245.
    View in: PubMed
    Score: 0.213
  9. Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival. NPJ Precis Oncol. 2017; 1.
    View in: PubMed
    Score: 0.191
  10. New Directions in Anti-Angiogenic Therapy for Glioblastoma. Neurotherapeutics. 2017 04; 14(2):321-332.
    View in: PubMed
    Score: 0.189
  11. Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages. Proc Natl Acad Sci U S A. 2016 Apr 19; 113(16):4470-5.
    View in: PubMed
    Score: 0.176
  12. Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival. Proc Natl Acad Sci U S A. 2016 Apr 19; 113(16):4476-81.
    View in: PubMed
    Score: 0.176
  13. Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma. J Clin Oncol. 2015 Apr 01; 33(10):1197-213.
    View in: PubMed
    Score: 0.163
  14. Vessel caliber--a potential MRI biomarker of tumour response in clinical trials. Nat Rev Clin Oncol. 2014 Oct; 11(10):566-84.
    View in: PubMed
    Score: 0.157
  15. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol. 2013 Sep 10; 31(26):3212-8.
    View in: PubMed
    Score: 0.147
  16. Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma. Neuro Oncol. 2013 Aug; 15(8):1079-87.
    View in: PubMed
    Score: 0.145
  17. Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res. 2012 Jan 15; 72(2):402-7.
    View in: PubMed
    Score: 0.130
  18. Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape. Cancer Res. 2011 Jan 01; 71(1):19-28.
    View in: PubMed
    Score: 0.122
  19. Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide. J Neurooncol. 2011 Jun; 103(2):325-32.
    View in: PubMed
    Score: 0.120
  20. A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res. 2009 Jul 01; 69(13):5296-300.
    View in: PubMed
    Score: 0.110
  21. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol. 2009 Jun; 6(6):327-38.
    View in: PubMed
    Score: 0.110
  22. Angiogenesis as a therapeutic target in malignant gliomas. Oncologist. 2009 Jun; 14(6):621-36.
    View in: PubMed
    Score: 0.110
  23. Phase Ib study of cediranib in combination with daily temozolomide and radiation in patients with newly diagnosed glioblastoma. J Clin Oncol. 2009 May 20; 27(15_suppl):e13010.
    View in: PubMed
    Score: 0.109
  24. Anti-vascular endothelial growth factor therapy for malignant glioma. Curr Neurol Neurosci Rep. 2009 May; 9(3):254-62.
    View in: PubMed
    Score: 0.109
  25. VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer. Nat Rev Clin Oncol. 2009 Apr; 6(4):229-36.
    View in: PubMed
    Score: 0.108
  26. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol. 2009 May 20; 27(15):2542-52.
    View in: PubMed
    Score: 0.108
  27. Advances in neuroimaging techniques for the evaluation of tumor growth, vascular permeability, and angiogenesis in gliomas. Curr Opin Neurol. 2008 Dec; 21(6):728-35.
    View in: PubMed
    Score: 0.106
  28. Response criteria for glioma. Nat Clin Pract Oncol. 2008 Nov; 5(11):634-44.
    View in: PubMed
    Score: 0.104
  29. Characterization of blood vessels in brain autopsies of GBM patients who received antiangiogenic treatment. J Clin Oncol. 2008 May 20; 26(15_suppl):2009.
    View in: PubMed
    Score: 0.102
  30. A comparative study of circulating endothelial cells (CECs) and circulating progenitor cells (CPCs) kinetics in four multidisciplinary phase II studies of antiangiogenic agents. J Clin Oncol. 2008 May 20; 26(15_suppl):3544.
    View in: PubMed
    Score: 0.102
  31. Antiangiogenic agents for the treatment of glioblastoma. Expert Opin Investig Drugs. 2007 Dec; 16(12):1895-908.
    View in: PubMed
    Score: 0.099
  32. VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. Trends Mol Med. 2007 Jun; 13(6):223-30.
    View in: PubMed
    Score: 0.095
  33. Publisher Correction: Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI. Sci Rep. 2019 Jun 14; 9(1):8721.
    View in: PubMed
    Score: 0.055
  34. Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI. Sci Rep. 2018 11 20; 8(1):17062.
    View in: PubMed
    Score: 0.053
  35. Phase I and Biomarker Study of Plerixafor and Bevacizumab in Recurrent High-Grade Glioma. Clin Cancer Res. 2018 10 01; 24(19):4643-4649.
    View in: PubMed
    Score: 0.051
  36. A Glial Signature and Wnt7 Signaling Regulate Glioma-Vascular Interactions and Tumor Microenvironment. Cancer Cell. 2018 05 14; 33(5):874-889.e7.
    View in: PubMed
    Score: 0.051
  37. Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma. J Neurooncol. 2017 02; 131(3):603-610.
    View in: PubMed
    Score: 0.046
  38. A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma. Neuro Oncol. 2015 Oct; 17(10):1386-92.
    View in: PubMed
    Score: 0.041
  39. A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients. Clin Cancer Res. 2015 Aug 15; 21(16):3610-8.
    View in: PubMed
    Score: 0.041
  40. Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation. Oncologist. 2014 Jan; 19(1):75-81.
    View in: PubMed
    Score: 0.037
  41. Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy. Nat Med. 2013 Sep; 19(9):1178-83.
    View in: PubMed
    Score: 0.037
  42. T(1)- and T(2)(*)-dominant extravasation correction in DSC-MRI: part II-predicting patient outcome after a single dose of cediranib in recurrent glioblastoma patients. J Cereb Blood Flow Metab. 2011 Oct; 31(10):2054-64.
    View in: PubMed
    Score: 0.031
  43. Serial magnetic resonance spectroscopy reveals a direct metabolic effect of cediranib in glioblastoma. Cancer Res. 2011 Jun 01; 71(11):3745-52.
    View in: PubMed
    Score: 0.031
  44. Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib. Neuro Oncol. 2010 May; 12(5):466-72.
    View in: PubMed
    Score: 0.029
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.